| Description | Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulatory agent is utilized in the research of autoimmune disorders, including inflammatory bowel disease (IBD), and is explored for its potential in fatty liver disease research through FXR targeting. |
| Synonyms | 4sc-101 hemicalcium, SC12267 hemicalcium, 4sc-101 hemicalcium ; SC12267 hemicalcium |
| molecular weight | 375.4 |
| Molecular formula | C20H18FNO4.1/2Ca |
| CAS | 1354012-90-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |